Cancer is a complex disease, driven by aberrant activity in numerous signaling pathways in even individual malignant cells. Epigenetic changes are critical mediators of these functional changes that drive and maintain the malignant phenotype. Changes in DNA methylation, histone acetylation and methylation, non-coding RNAs, post-translational modifications are all epigenetic drivers in cancer, independent of changes in the DNA sequence. These epigenetic alterations, once thought to be crucial only for the malignant phenotype maintenance, are now recognized as critical also for disrupting essential pathways that protect the cells from uncontrolled growth, longer survival and establishment in distant sites from the original tissue. In this review, we focus on DNA methylation and chromatin structure in cancer. While associated with cancer, the precise functional role of these alterations is an area of active research using emerging high-throughput approaches and bioinformatics analysis tools. Therefore, this review describes these high-throughput measurement technologies, public domain databases for highthroughput epigenetic data in tumors and model systems, and bioinformatics algorithms for their analysis. Advances in bioinformatics data integration techniques that combine these epigenetic data with genomics data are essential to infer the function of specific epigenetic alterations in cancer, and are therefore also a focus of this review. Future studies using these emerging technologies will elucidate how alterations in the cancer epigenome cooperate with genetic aberrations to cause tumorigenesis initiation and progression. This deeper understanding is essential to future studies that will precisely infer patients' prognosis and select patients who will be responsive to emerging epigenetic therapies.
INTRODUCTION
Cancer is a complex disease. The malignant transformation is a multi-step process associated with the accumulation of numerous molecular alterations. These molecular changes impact cellular function within the tumor, its microenvironment, and culminate in the hallmarks of cancer: sustained proliferative signaling, resistance to apoptosis, senescence, angiogenesis, invasion and metastasis, deregulating cellular energetics, avoiding immune destruction, tumorpromoting inflammation, and genome instability and mutation [1] . Numerous genetic alterations (mutations, loss of heterozygosity, deletions, insertions, aneuploidy, etc.) have been associated with carcinogenesis [2] and can sometimes present a clear oncogenic function being considered as cancer driver mutations in such cases [3] . All these genetic alterations ultimately result in aberrant gene expression. However, the landscape of genetic alterations is insufficient to explain the pervasive gene expression changes and alterations to cellular function in cancer [4] .
For example, according to the Knudson two-hit hypothesis deletions on both alleles of tumor suppressor genes block the mechanisms in the cell that prevent aberrant cellular growth [5, 6] . In many cancers, one of these alterations (or "hits") is a hereditary or somatic mutation in a tumor suppressor gene and the second "hit" an acquired mutation or copy number loss in the other allele. Nevertheless, sometimes the second genetic "hit" is not observed, but clear changes in gene expression are found and can be explained by the epigenetic alterations [4] .
Epigenetic changes are as pervasive in cancer as genetic alterations, and likely are responsible for the hidden source of variation in cancer [4] . Epigenetic changes are heritable traits that impact the phenotype by interfering with gene expression without making changes in the DNA sequence [7, 8] . These epigenetic mechanisms include: DNA methylation, chromatin remodeling and, more recently, non-coding RNAs, binding of regulatory proteins, such as CTCF, BORIS or diverse transcription factors also affects chromatin states [9, 10] .
Epigenetic events can also act concomitantly with other molecular processes in normal states or disease to have persistent gene expression and functional alterations. For example, epigenetic alterations that impact transcription factor binding can explain genome-wide transcription dysregulation that are not associated with genetic variation in cancer [11] . Recent studies have also found that cancer mutations are associated with the chromatin structure of the tissue of origin [12] . These mutations are often enriched in regions of closed chromatin, which are inaccessible to DNA repair genes during replication [12] . Therefore, alterations to chromatin structure may be critical early drivers of cancer.
Epigenetic alterations with functional impacts on gene expression in individual tumor remain key targets of interest because they can be reverted by the use of specific epigenetic therapies [9, [13] [14] [15] . Therefore, this review focuses on describing resources for reversible epigenetic events that result or that are directly associated with changes in chromatin organization: DNA methylation and chromatin organization (Figure 1 ). We describe techniques, model systems, and data resources with high throughput epigenetic data in cancer. We also discuss the emerging bioinformatics techniques for analysis of these data and their integration with highthroughput transcriptional data in cancer. Together, these experimental and computational tools are essential to find the hidden sources of genetic variation in cancer and for precision medicine of novel epigenetic therapies. is more open, while non-active genes (transcription silencing) are found in regions where the chromatin is more compact. Active chromatin areas are characterized by unmethylated DNA CpG sites, histone acetylation and histone active markers, such as H3K4 and H3K36 methylation. The inverse alterations (methylated CpG sites, histone deacetylation and repressive histone markers) are observed in areas of condensed chromatin, where nucleosomes are positioned closer to each other and DNA accessibility to transcription factors is blocked by the DNA structure and also presence of protein complexes that regulate this compact conformation.
Reversible epigenetic events

DNA Methylation
DNA methylation, the addition of a methyl radical (CH 3 ) to the 5-carbon on cytosine residues (5mC) in CpG dinucleotides [16] [17] [18] , is a normal event with critical roles during different stages of human development, silencing of genome repetitive elements, protection against the integration of viral sequences, genomic imprinting, X chromosome inactivation in females and transcriptional regulation [7, 18, 19] . In cancer cells, CpG methylation is assessed in tumors relative to that in normal tissues. Removal of CpG methylation specific to cancer cells is referred to as hypomethylation and CpG methylation specific to cancer cells is referred to as aberrant methylation or hypermethylation.
DNA methylation changes to regulatory elements (promoters, insulators, enhancers) with CpGconcentrated regions known as CpG islands (CGI) have been a focus within genome-wide epigenetic studies. These CpGI are extensive sequences (~800 nucleotides in average, range 200-10,000) with higher concentration of CpGs (~10%) and C+G content (>55%) when compared to the rest of the genome (1% of CpG and 42% C+G content) [20, 21] . DNA methylation changes outside of CpG island regions or their "CpG shores" are also apparent.
The methylation patterns in these shores are highly tissue-specific in normal human samples [22] . The alterations in DNA methylation in cancer extend well beyond CpG island shores [22, 23] . These methylation changes have far greater variability than that of normal samples and methylation profiles for some regions distant from CpG islands may be more similar to other normal tissues than the cell of origin [22] . The impact and function of these distant alterations remain poorly understood.
Genome-wide hypomethylation was the first described epigenetic aberration in cancer [24] .
Loss of normal DNA methylation levels is associated with genome instability and aneuploidy, reactivation of transposable elements, and loss of imprinting [24, 25] . Hypermethylation is associated with gene silencing [26] [27] [28] , since this event can (1) block transcription directly, by blocking transcription factors binding to their specific sites; or indirectly, by (2) recruitment of protein complexes with high affinity for methylated DNA (methyl-binding domain complexes -MBDs) ( Figure 1 ) [16, 17, 19, 27, [29] [30] [31] [32] . Therefore, hypermethylation can serve as the second alteration to tumor suppressor genes in Knudson's two-hit hypothesis [4, 5, [33] [34] [35] .
Hypermethylation of gene promoters not only affects the expression of protein coding genes but also constitutes a mechanism to regulate the expression of various noncoding RNAs, some of which have a role in malignant transformation [4] .
Chromatin modifications
Histone marks are post-translational modifications of core histone proteins that affect chromatin structure [36] . These modifications correlate with open or closed conformations of chromatin, drive differential access of genes to transcription factors and regulatory proteins ( Figure 1 ). Therefore, histone alterations are a facile mechanism for cells to dynamically regulate their gene expression. They are frequently de-regulated in complex diseases, including cancer [4] .
Changes in chromatin landscape frequently co-occur with alterations of DNA methylation signals. Histone methylation (20 variants) and acetylation (18 variants) are the most common modifications that mainly target lysine residues of histone tails [37] . Many more modifications include phosphorylation, ubiquitylation, and glycosylation, which spread to other amino acid residues, such as arginine, serine and threonine [38] [39] [40] [41] . The critical amino-acids of histone tails most commonly used for diverse modification are found mutated in cancer [42] [43] [44] . There are multiple regulatory proteins that write, read and/or erase histone marks [45] , many of which also get dysregulated in diseased cells [46] . Because histone marks have stable covalent structures, they can be inherited during cell division and DNA duplication and serve as strong disease markers [47] . Analysis of chromatin structure and its regulatory machinery are key in developing epigenetics therapies.
High-throughput Platforms for Epigenetic Analysis
In the current era of high-throughput data, new technologies to measure the genome-wide state of DNA methylation and chromatin structure are actively emerging ( Figure 2 ). Following the history of the field, many measurement platforms were first developed in microarrays and adapted to next generation sequencing technologies. As a result, cancer biologists have access to unprecedented measurement technologies that are able to assess genome-wide DNA methylation and chromatin modifications, accessibility, protein interactions, and binding. Here in this review, we will briefly describe high-throughput approaches for epigenetic mapping from DNA methylation, chromatin modification markers and chromatin structure commonly used in cancer genomics, with details about each measurement technology in Supplemental File 1. There is a wide variety of methods that can be used to characterize epigenetic alterations. Currently, the most common genome-wide approaches allows the identification of nucleosome-free regions (DNaseI-Seq, MNase-Seq, FAIRE-Seq, ATAC-Seq), protein-mediated DNA interaction sites (Hi-C, 5-C), histone marks and DNA binding proteins (ChIP-Seq, ChIA-PET) and DNA methylation (array hybridization, whole genome bisulfite sequencing, MBD-Seq).
DNA Methylation
Numerous microarray and sequencing-based technologies have been used to measure DNA methylation ( Table 1) . DNA methylation can be measured on native DNA through recognition of methylated cytosines by antibodies (Methylated DNA immunoprecipitation) or by conjugated Methyl-CpG Binding Proteins (MBP) [51] . The antibodies can also recognize DNA methylationassociated proteins such as MeCP2 with chromatin immunoprecipitation (ChIP)-based technologies, which can be used to estimate DNA methylation. Massively parallel next generation sequencing or arrays to measure DNA methylation-enriched fragments provides quantitative whole-genome evaluation of DNA methylation and allows estimating a high resolution of mCpG sites . False negatives may arise from incomplete binding of the antibodies.
Nonetheless, these techniques have strong true positive rates due to the nanomolar binding affinity to symmetrically methylated CpG. Arrays). The ratio between methylated and unmethylated signals is proportional to the methylation level of each specific CpG. Bisulfite conversion reduces genome complexity from four nucleotide types to three, except for the few methylated CpG sites, in many cases making alignment to the reference genome or annealing to the particular probe non-unique and introducing errors into the quantification and interpretation . Moreover, the results will depend on the efficiency of bisulfite-conversion step. Therefore, new bioinformatics techniques for preprocessing bisulfite-based data remain a critical challenge preceding the analysis of DNA methylation data in cancer. Comparison of the epigenetic changes across reads enables quantification of intra-tumor variability of epigenetic alterations and of the specificity of epigenetic alterations in a single locus [60] . In spite of the challenges with normalization, these measurements of epigenetic variation within tumors are only possible with bisulfite sequencing techniques. Single cell bisulfite sequencing technologies are emerging to further refine the variability of the epigenetic landscape within tumor samples.
Chromatin Structure and Interaction
Chromatin is the DNA-protein complex that compacts and protects the genomic DNA within the cellular nucleus and the carrier of epigenetic information, with techniques to measure its structure and interaction domains summarized in Table 2 . Public domain databases of histone antibody specificity have been released to provide optimal signal for measurements of histone modifications with ChIP [80] .
Other volume that is not available for most primary cancer samples.
Model Systems
Ideally, the extensive epigenetic measurement technologies will be applied to primary tumors samples to measure their epigenetic state. Such extensive profiling of DNA methylation has been performed extensively across measurement technologies. Measuring chromatin, however, proves to be more challenging. Many chromatin assays require large quantities of high quality DNA and the intact chromatin structure. However, tumor samples that are available for profiling are typically small and use preservation techniques that may degrade the quality of the DNA or chromatin structure. Therefore, both in vitro and in vivo model systems of cancer are essential to determining the epigenetic state of many cancer types ( Figure 3 ). Extending these techniques to humanized PDXs is essential to determine the impact of the immune system to perform preclinical studies correlating the functional role of epigenetics on the efficacy of epigenetic inhibitors and immunotherapy. 
Epigenetics Data Resources
Numerous international high-throughput genomics databases from thousands of tumor samples and model systems are available in the public domain, reviewed in [81] . However, similar resources for epigenetics in cancer are still more limited. Recent efforts to organize and share large epigenomic datasets have created publicly available resources for discovery and validation in cancer. Cancer-specific resources range in specificity, including large, multi-assay datasets across epigenetics data modalities, such as DNA methylation, histones, and chromatin structure. DNA methylation of 1,001 cancer cell lines was measured with Illumina 450K arrays along with therapeutic sensitivity, copy number, somatic mutations, and gene expression [82] and is freely available from the Gene Expression Omnibus (GEO Series GSE68379). Both the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) contain microarray measurements of DNA methylation in primary tumors and cancer models. DNA methylation of tumors has been assessed with sequencing technologies in isolated studies from smaller groups, with corresponding data often deposited into sources including GEO [83] , dbGAP, and ArrayExpress [84] . However, these sequencing-based DNA methylation data are available for fewer primary tumors than the array-based data from international consortia.
Currently, there are no databases of chromatin structure in primary tumors due to dual challenge of sample quality and quantity described above. Therefore, projects such as ENCODE contain ChIP-seq data of histone marks and chromatin accessibility in numerous cancer cell lines in place of primary tumors [85] . More narrow databases, like FANTOM's efforts to characterize promoter utilization in different cell types, including 250 cancer cell lines [86] . As with DNA methylation, chromatin measurements in other model organisms have been performed by individual labs. Data of chromatin structure of healthy samples from projects such as the Epigenomics Roadmap [87] have found unanticipated associations with mutations in cancer samples [88] . Therefore, comparison of epigenetics data unrelated to cancer with cancer genomics datasets in other sources may also yield novel insights into the functional impacts of epigenetic regulation in cancer.
In spite of the breadth of public domain chromatin datasets, there is a lack of centralized resources to obtain the wide range of data from numerous studies in a centralized platform.
Cistrome is a centralized database of histone modifications [89] , which includes Cistrome Cancer to integrate TCGA gene expression data with public ChIP-seq data to determine functional histone modifications in cancer. Another database, EnhancerAtlas (enhanceratlas.org), was specially designed for enhancer analysis and visualization across studies [90] . It contains enhancer annotation for more than 100 cell/tissue types, including both normal and cancer cells. The enhancer annotation was supported by multiple, independent experimental evidences such as chromatin accessibility, histone modifications and eRNAs.
Furthermore, the database provides several analytic tools so that the users can compare the enhancer activity across different cell types or connect the enhancers and target genes.
Determining the function of epigenetics alterations in cancer requires integration with genomics data. Ideally, these measurements would be made for the same tumor. Most prominently, the 
Bioinformatics Techniques
For all epigenetic data, be it microarray or next generation sequencing, the bioinformatics pipeline follows three major steps: (1) quality control, (2) preprocessing, and (3) analysis [91] .
Typically, each of these steps is performed independently for each study and data modality. The bioinformatics techniques for each of these steps are active areas of research, with the maturity of the techniques matching the age of each measurement technology. Once each dataset is understood independently, epigenetic data can be integrated with other cancer genomics data to determine its functional impact. Such robust, integrated techniques are emerging in bioinformatics. Still, further research in data integration is essential to establish epigenetic drivers of carcinogenesis and therapeutic response for precision medicine.
DNA methylation normalization and analysis
Preprocessing high throughput epigenetic data is critical to obtain accurate results, and techniques for each measurement technology are described in detail in Supplemental File 1. For microarrrays, this entails image processing and normalizing probe intensities. Whole Genome Bisulfite Sequencing (WGBS) techniques require alignment to a reference genome and quantification similar to most second-generation bulk RNA sequencing techniques. As such, most preprocessing pipelines rely on modification of algorithms developed for RNA sequencing. MBD-Seq data adapts peak calling algorithms from ChIP-seq such as MACS [92] to distinguish genomic regions that are methylated. Whereas MBD-seq is non-quantitative, both microarrays and WGBS provide quantitative measurements of the percentage of methylation at each probe or genome coordinate. These estimates can be allele specific for stranded WGBS. Nonetheless, the false positive rate for MBD-Seq is far lower than arrays or WGBS.
As a high-throughput technique, signal from DNA methylation data is often combined with technical artifacts independent of the biological conditions similar to the batch effects established in gene expression studies [93] . These artifacts are most predominant when comparing data across distinct studies, but may also be present within large cohort studies such as TCGA. Visualization tools have been developed to assess these technical artifacts from DNA methylation arrays [94, 95] and are an important first step to any analysis of large cohort studies.
Many batch correction techniques developed for gene expression microarrays [96, 97] have been applied to correct for technical artifacts in DNA methylation arrays [98] . However, care must be taken when adapting these algorithms to maintain the distribution of DNA methylation values. Therefore, normalization techniques that account for this distribution [99, 100] and tissue specificity [101] may be better suited to accounting for batch effects in DNA methylation arrays in cancer. Similar to gene expression microarrays, batch correction techniques must be selected in order to preserve signal for the desired analysis [102] . Signaling-based measurements of DNA methylation are not immune to batch effects. However, these have been less studied than DNA methylation arrays. Gene level estimates of DNA methylation from bisulfite sequencing could be corrected with standard expression based techniques, with the same caveats that apply to microarrays. However, these techniques will not extend to locus-specific methylation estimates or DNA methylation from MBD-sequencing. In all cases, obtaining accurate signal requires considering batch effects as part of the experimental design, most especially avoiding perfect confounding between known technical artifacts (e.g., site of tissue source, sampling batch, etc) and experimental conditions [93] .
Many analytic tools for DNA methylation data were developed from well-established procedures for gene expression analysis. Accordingly, techniques for detecting robust differences between two or more conditions are the most ubiquitous and reviewed extensively in [103] . This is especially true for work in cancer, in which case-control studies and comparisons of matched tumor and normal tissue from the same individual lend themselves to this type of analysis.
Wilcoxon rank-sum tests and t tests comparing the methylation status of individual genes between two or more groups are the most basic and commonly employed analysis. To have an impact on expression, DNA methylation changes would ideally be observed over an entire region of the genome. Therefore, bump-hunting algorithms have also been developed to determine differentially that distinguish sample phenotypes [104] . Variably methylated regions inferred with bump-hunting [104] and outlier based analysis algorithms [105] are ideally suited to capture inter-tumor heterogeneity in DNA methylation alterations.
Because MBD-seq data obtains calls of methylated regions, alternative statistical methods either comparing the signal relative to input control or comparing binary calls necessary for its analysis. Techniques to compare peaks across conditions are currently emerging in the literature [106, 107] , and are primarily divided into linear models comparing peaks similar to DMRs, such as DiffBind [108] , hidden Markov Models, such as ChiPDiff [109] and ChromHMM [110] , or whole-genome correlations, such as StereoGene [111] and GenometriCorr [112] . For all data platforms, more advanced methods using mixture models, Shannon entropy, logistic regression, non-negative matrix factorization, clustering, feature selection, and correlation to help power between group comparisons.
Chromatin analysis
The vast majority of techniques to determine chromatin state and binding are derived from ChIP-seq techniques. Therefore, these data use similar preprocessing and differential analysis techniques to those described for MBD-Seq data. Robust standards for quality control and preprocessing were adopted by ENCODE as gold standards for all chromatin based analyses [113] . Determining the chromatin structure specific to cancer cells or cancer subtypes requires differential binding algorithms similar to those described in analysis of MBD-Seq data and reviewed in [106] . In contrast, chromosomal capture methods, i.e. 5C and HiC, produce multiple values representing interaction profiles for each gene. Current bioinformatic tools to analyze this data are summarized in [114] and rapidly developing.
Determining Functional Impacts of Epigenetic Modifications with Data Integration
Regardless of the data type, biology defines specific relationships between epigenetic regulation and gene or protein expression. Thus, identifying a functional regulatory role from the resulting epigenetic data requires associating the changes with alterations in gene or protein expression.
However, technical heterogeneity and confounding from non-biological artifacts, such as batch effects [93] , library preparation [115] and antibody quality [116] , are problematic within a single data type and can easily grow to be prohibitively complex when integrating across both biological and technical mechanisms [117] .
To prevent complications from undesired technical variation, most integrated techniques focus on associating separate analyses of each data type by the co-localization of significant results at the same genetic location, e.g. hypomethylation of the promoter for a given gene is found to be associated with an increase in the gene's expression level. These methods require matched samples for each set of comparisons a major limitation when dealing with a finite amount of tissue. Additionally, as a given gene in a subtype of cancer is likely to be affected in only a small fraction of individuals, loci based approaches can be unsuccessful in detecting meaningful biological relationships. Thus, techniques, such as OGSA [118] and RTOPPER [119] seek to increase power and biological inference by integrating these univariate differential results over pathway and genes sets. Algorithms integrating these statistics can be adapted to analyze epigenetic regulation of gene expression from distinct genomics datasets from cohorts with similar study design, and need not necessarily have measurements from the same samples in all data modalities. Outlier based approaches for this integration, such as OGSA [118] , are best suited to capture inter-tumor heterogeneity of epigenetic pathway regulation.
In contrast to gene-based integration analyses, fully integrated analysis has additional power to identify genes or pathways that are often disrupted by multiple mechanisms but at low frequencies by any one mechanism. Unsupervised algorithms, such as iCluster [120] , Amaretto [121] and matrix factorization algorithms [122, 123] , search for patterns common in these diverse molecular components, regardless of regulatory relationships (Figure 4 ). Because of their reliance on the concurrence of positive signal, clustering techniques are unable to encode epigenetic silencing a major form of epigenetic regulation on gene expression. The CoGAPS algorithm finds patterns associated with coordinated DNA methylation and expression changes by encoding a distribution that DNA methylation silences gene expression [123] . Similar models of DNA methylation regulation of gene expression are employed to determine genes with a functional impact on cancer subtypes in the MethylMix algorithm [127] . Supervised algorithms overcome this limitation by comparing gene level associations with phenotype in all measurement platforms [124, 125] or in several measurement platforms for multiple pathway members [118, 119, 126] . However, role of DNA methylation in the gene body is not associated with gene expression silencing, and thus more complex to integrate with these techniques.
Therefore, further work is needed to develop robust bioinformatics integration algorithms that encode regulatory relationships between genetic and epigenetic alterations as research refines their interrelationship biologically.
Expanding to the use of biologically driven priors to chromatin data, where different marks or spatial relationships have different regulatory effects, presents additional challenges, and may require adapting techniques developed for dealing with multiple targets in miRNA expression to the chromatin landscape [117, 118, 125] . Time course methods such as miRDREM have also been developed to determine the timing of activity of miRNA by integrating their expression with that of mRNA targets [128] . These techniques could readily be adapted to determine the functional impacts of chromatin regulation from time course data of cancer development, metastasis, and therapeutic resistance emerging in the literature. Bioinformatics methods are currently being developed that focus on aggregating over epigenetic modifications with similar effects on gene expression, i.e. all repressive or all activating. The ELMER algorithm was developed to incorporate genome-wide maps of enhancers and transcription factors with methylation and expression data to determine epigenetic regulation of transcription factors in cancer [129] . Encoding ways to account to multiple often-conflicting modes of regulation through dysregulation techniques [130] remains a promising avenue for future research. All the algorithms for integration described above are based upon comparisons of gene-or geneset-level summaries of both the epigenetics and genomics data to associate them with phenotypes in cancer. As is the case for CpG Islands [22] , epigenetic alterations in non-coding regions of the genome have critical functional alterations in cancer. In these cases, genomewide associations of epigenetic alterations with the genome, transcriptome, and proteome are essential to determine their functional impact. GenometriCorr [112] , which computes the correlation between sets of genomic intervals, can be used to integrate different types of datasuch as the location of gene promoters and transcription factor binding sites or other annotation.
For a pair of interval-represented datasets, GenometriCorr estimates a variety of correlations that are based on interval overlaps, on relative relative genomic distances, and on absolute genomic distances. GenometriCorr is limited to correlation between binary calls along genome tracks and thus requires an interval calling procedure, e.g. MACS [131] to prepare the interval data for coverage-like (numeric) datasets. In contrast, StereoGene [111] does not require such an identification of intervals. StereoGene uses kernel methods to correlate genome-wide patterns in intensity between two data sets. In this case, epigenetic and genomic profiles may 
DISCUSSION
Elucidating the relationships between different epigenetic mechanisms and their regulation of gene expression is essential to finding hidden sources of variation in cancer and therapeutic selection. New high-throughput measurement technologies enable unprecedented, quantitative measurements of the epigenetic state in cancers. For DNA methylation, these techniques can be applied readily to both primary tumors and model organisms. Therefore, the functional impact of methylation alterations can be assessed bioinformatically in targeted experiments on model organisms and across sample population. On the other hand, chromatin assays require higher quality and quantity samples that are typical not feasible for preserved tumor samples or biopsies. As a result, chromatin measurements are typically limited to model organisms. In the case of DNA methylation, the epigenetic landscape of cell line models has been shown to vary significantly from that of primary tumors relative to patient-derived xenografts [132] . We anticipate similar discrepancies between model organisms and primary tumors in the chromatin landscape. Thus, advances that adapt chromatin measurement techniques to primary tumor samples are essential to cancer epigenetics.
Databases with epigenetic and genomic data, such as TCGA, ENCODE, and FANTOM are an important step toward achieving this goal. Individually, these large public domain data sets have fueled algorithm development and understanding of epigenetic and tumor based gene expression changes, respectively. While TCGA contains DNA methylation, gene expression, and proteomic data in thousands of primary tumors across cancer types, it lacks chromatin data.
Chromatin and transcriptional data are available for numerous cancer cell lines in ENCODE and FANTOM, but these databases lack DNA methylation data and data from primary tumors.
However, interactions between DNA methylation and chromatin structure are essential in functional epigenetic regulation. Therefore, it is essential to develop a comprehensive database of matched epigenetic, genetic, and phenotypic data. A comprehensive catalog is especially important for primary tissue samples where cellular heterogeneity compounds the effect of interindividual heterogeneity further obscuring the underlying drivers of disease.
Numerous bioinformatics techniques have been developed to preprocess and analyze singleplatform data for DNA methylation and chromatin structure. However, establishing a functional link in cancer requires further identification of epigenetic alterations that are associated with gene expression, protein, and phenotypic changes. Integrating data across measurement platforms is essential to establish these functional relationships. To date, most of these techniques are limited to correlations between genes or common clusters shared across datasets. New integrated bioinformatics techniques are essential to model and distinguish different forms of epigenetic regulation in driving tumor heterogeneity and ultimately cancer.
While integrated analyses are emerging, few tools are designed to encode and test these regulatory relationships directly. Determining the true epigenetic regulatory mechanisms and drivers of cancer pathology will be essential for precision medicine with emerging epigenetic therapies.
KEY POINTS
• Epigenetic alterations compliment genomic alterations during cancer progression and therapeutic response.
• High-throughput measurement technologies can characterize the epigenetic landscape of tumors and model organisms.
• Epigenetic data in large panels of human tumors and cell lines are available from large research consortium.
• Bioinformatics algorithms that integrate epigenetic data with genomics data are essential to determine the function of epigenetic alterations in cancer.
